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N E U R O P H Y S I O L O G Y
High-throughput screening for selective appetite 
modulators: A multibehavioral and translational drug 
discovery strategy
Josua Jordi1,2*, Drago Guggiana-Nilo1, Andrew D Bolton1, Srishti Prabha1, Kaitlyn Ballotti1, 
Kristian Herrera1, Andrew J. Rennekamp3,4,5, Randall T. Peterson3,4,5,  
Thomas A. Lutz2, Florian Engert1*
How appetite is modulated by physiological, contextual, or pharmacological influence is still unclear. Specifically, 
the discovery of appetite modulators is compromised by the abundance of side effects that usually limit in vivo 
drug action. We set out to identify neuroactive drugs that trigger only their intended single behavioral change, 
which would provide great therapeutic advantages. To identify these ideal bioactive small molecules, we quanti-
fied the impact of more than 10,000 compounds on an extended series of different larval zebrafish behaviors using 
an in vivo imaging strategy. Known appetite-modulating drugs altered feeding and a pleiotropy of behaviors. 
Using this multibehavioral strategy as an active filter for behavioral side effects, we identified previously uniden-
tified compounds that selectively increased or reduced food intake by more than 50%. The general applicability 
of this strategy is shown by validation in mice. Mechanistically, most candidate compounds were independent of 
the main neuro transmitter systems. In addition, we identified compounds with multibehavioral impact, and cor-
relational comparison of these profiles with those of known drugs allowed for the prediction of their mechanism 
of action. Our results illustrate an unbiased and translational drug discovery strategy for ideal psychoactive 
compounds and identified selective appetite modulators in two vertebrate species.
INTRODUCTION
From an evolutionary, as well as a clinical, perspective, feeding rep­
resents a fundamental behavior, as nutritional supply is critical for 
survival and eating disorders are a rapidly growing prevalent health 
problem (1–3). Extreme lack of appetite, i.e., anorexia nervosa, causes 
irreversible physiological damage, while augmented food intake 
primarily promotes obesity, with a sedentary lifestyle and poly­
genetic mutations favoring disease onset (1–3). Managing nutritional 
intake is a key intervention strategy; however, to date, the pharma­
cological toolkit to selectively modulate food intake does not exist. 
Independent of their clinical relevance, selective modulators of 
appetite would serve a valuable role in providing targeted perturba­
tions and thereby entry points into the neural circuits underlying 
the control of feeding behavior in many animal model systems. His­
torically, most appetite effectors provoked unintentional side effects, 
illustrating one of the challenges in psychoactive drug discovery 
(4, 5). One of these cautionary examples is the effective appetite sup­
pressant rimonabant, a cannabinoid receptor 1 antagonist, which 
also causes anxiety and depression (6). This lack in specificity limits 
the usefulness of these drugs with respect to therapeutic interven­
tion and constrains their use in the targeted perturbation of neural 
circuits when the goal is the discovery of general principles regulat­
ing feeding behavior. Therefore, a priority in drug discovery for 
therapeutic and basic research goals needs to include a description 
of general behavioral impact and drug selectivity. Both should be­
come a standard requirement in preclinical development (7, 8).
Mainstream drug discovery efforts focus on protein targets using 
simple in vitro or cellular screens to identify small molecules or bio­
logics as modulators (9). The quality of the target correlates with 
success, and consequently, an in­depth molecular characterization 
underlying a phenotype is a prerequisite. Behaviors, such as food 
intake, are not understood at the molecular level, which strongly 
limits the reductionist approach of target­driven drug discovery. To 
date, target­based approaches are far less successful at identifying 
first­in­class drugs compared to holistic and unbiased phenotypic 
strategies, particularly in central nervous system (CNS) drug dis­
covery (9). Furthermore, in vivo drug efficacy is a major obstacle 
because traditional drug screening methods do not mimic whole­ 
organism dynamics, e.g., the blood­brain barrier. To tackle these 
problems, we designed a high­throughput chemical screen quanti­
fying the dynamics of food intake in live animals. Such an in vivo 
phenotype screen captures the complexity of whole organisms and 
makes compounds’ in vivo bioactivity and toxicity part of the initial 
screening phase. Here, the challenge is to quantify a complex phe­
notype like food intake on a large scale, which is normally con­
strained by the animal model under investigation. Rodents are not 
an optimal choice for initial high­throughput screening because 
their large size, generation time, and drug availability limit screen 
scale (10–12). A valid alternative is the larval zebrafish, a vertebrate 
roughly 4 mm long, which shares overall anatomy, physiology, and 
large parts of the genome with humans (13, 14). The small size en­
ables miniaturization and makes the zebrafish larva an attractive model 
organism to screen for previously unidentified  appetite modulators 
in vivo. We further demonstrate that a subset of specific, promising 
drug targets from the zebrafish study are also effective in a mouse model. 
Using this multibehavioral strategy as an active filter for behavioral 
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side effects, we aimed to identify ideal selective appetite modulators. 
Overall, this multibehavior approach represents an innovative and 
unbiased strategy for ideal psychoactive drug discovery in vivo.
RESULTS
The homeostatic state modulates feeding behavior  
in zebrafish
Toward identifying feeding selective compounds, we designed a 
whole­ organism high­throughput screening system that enabled us 
to quantify, in addition to feeding, a series of other vital behaviors 
in larval zebrafish. Larvae growth and development were standard­
ized to guarantee similar baseline conditions in all experimental 
animals (Fig. 1A and Supplementary Text). Before behavioral phe­
notyping at 7 days post­fertilization (dpf ), the larvae were fasted for 
different time periods and placed into a 96­well plate. Subsequently, 
a custom­built imaging platform detected several distinct behavioral 
phenotypes in all 96 animals simultaneously (Fig. 1B). First, larval 
zebrafish hunt and ingest live paramecia, a unicellular protozoan 
roughly 100 m in size, and thereby enable the quantitative charac­
terization of feeding behavior (15). Here, we fluorescently labeled 
the prey, and the imaging platform quantified larval food intake by 
detecting intestinal fluorescence content for 2 hours (Fig. 1C). Bio­
logically grounded curve­fitting algorithms enabled us to extract key 
characteristics of feeding behavior, namely, total food intake, initial 
intake rate, and digestion rate (15). Different fasting periods modu­
lated these parameters analogous to observation in adult rodents 
and humans (Fig. 1, D to F). Second, in parallel to the fluorescent 
Fig. 1. Homeostatic state modulates feeding behavior but not spontaneous activity, arousal to visual or acoustic signals, or habituation in zebrafish larvae. 
(A) Zebrafish larvae were raised under controlled conditions until 7 dpf, loaded into a well of a 96-well plate, and fasted for different time periods before assessment of 
distinct behaviors. (B) A custom-built imaging platform can quantify larval feeding behavior by measuring intestinal food content if combined with feeding fluorescently 
labeled live prey, larval locomotion by tracking swimming behavior, larval arousal by presenting visual and acoustic signals, and larval habituation (nonassociative learn-
ing) by repeatedly presenting inconsequential stimuli. The two exemplary images show data quality used for larval activity tracking and larval intestinal food content 
quantification using two distinct invisible light sources. All measurements were acquired under daylight conditions. Scale bars, 1 mm. (C) After different fasting periods, 
larvae were given access to fluorescently labeled paramecia, and their intestinal food content was quantified for 2 hours. Using a biological inspired curve-fitting algo-
rithm, we extracted total food intake (D), initial intake rate (E), and digestion rate (F) (15) (n = 48; one-way ANOVA, Dunnett’s post test, ***P < 0.001). (G) Simultaneously, 
larval locomotor activity was tracked for 2 hours (n = 48; lc, line crosses). (H) Larval zebrafish react to dark flashes with increased motor output (50). After different fasting 
periods, larvae were exposed to eight dark flashes [750-ms duration, 30-s interstimulus interval (ISI)] and their locomotion was quantified. The triggered average is shown 
(n = 48). (I) An acoustic stimulus triggers larval locomotion (51). Identical experiment as in (H), but here a single tap was presented instead of a dark flash (n = 48). 
(J) Zebrafish larvae habituate to repetitive, inconsequential stimuli (52). Here, we presented 30 sequential taps with a short ISI (2 s) to differently fasted larvae and quan-
tified larvae’s locomotor response. (K) The habituation metric is the activity ratio of the initial and last three taps indicated by the black bars (n = 48; one-way ANOVA, 
Dunnett’s post test, P > 0.05).
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feeding assay, we simultaneously tracked larval locomotion to quan­
tify their swimming activity for 2 hours (Fig. 1, B and G). Third, we 
presented short periods of darkness to which larval zebrafish react 
with an increased motor output (Fig. 1H). Fourth, we applied a sin­
gle mechanical tap to the plate, causing larvae to respond with a 
stereotypic startle response (Fig. 1I). Fifth, the larvae habituated to 
a series of high­frequency taps (Fig. 1, J and K). Neither spontaneous 
activity (Fig. 1G), responsiveness to visual (Fig. 1H) or acoustic 
(Fig. 1I) stimuli, nor habituation (Fig. 1, J and K) was affected by 
different fasting periods and their underlying homeostatic state, 
whereas feeding behavior (Fig. 1, C to F) was strongly modulated, 
indicating a lack of interdependence of these behaviors and, pos­
sibly, the underlying neuronal circuitry. All these behaviors were 
quantifiable in a multiwell plate and therefore amenable to large­
scale chemical screening.
Current appetite modulators are not selective for  
feeding behavior
To establish the value of the here developed multibehavioral strategy, 
we first tested many appetite­modulating drugs previously used in 
humans. Briefly, we pre­exposed 2­hour­fasted larval zebrafish to a 
single compound, as shown here for nicotine and rimonabant, be­
fore giving them access to live, fluorescently labeled prey (Fig. 2A). 
Subsequently, the custom­built imaging platform quantified larval 
food intake by detecting intestinal fluorescence content (Fig. 2, B to 
E) and tracked larval locomotion to quantify their spontaneous 
activity (Fig. 2F), responsiveness to visual (Fig. 2G) or acoustic 
(Fig. 2H) stimuli, habituation (Fig. 2I), and lethargy (Fig. 2J). Both 
nicotine and rimonabant significantly reduced food intake (Fig. 2, 
B to E). Additional nutritional and endocrinal interventions were 
previously demonstrated to have an analogous impact on feeding 
behavior in fish, rodents, and humans (15). Furthermore, nicotine 
increased spontaneous activity, yet had no significant impact on 
any other tested behaviors (Fig. 2, F to J). Rimonabant decreased 
spontaneous activity, reduced the habituation response, and modu­
lated lethargy, but had no impact on the response to visual stimuli 
(Fig. 2, F to J). In an effort to simplify behavioral quantification, we 
normalized each compound’s behavioral effect size to on­plate ve­
hicle controls (n ≥ 24 per plate) and condensed their quantitative 
behavioral impact into behavioral barcodes accounting for repro­
ducibility and effect size by an observer­independent approach 
(Fig. 2K, black box). Next, we tested additional appetite­modulating 
drugs previously used in humans and showed that all of these drugs 
phenocopied their behavioral effect in zebrafish larvae (Fig. 2K, first 
two columns; F1 and F2, orange box). Critically, all of these drugs 
altered a pleiotropy of larval behaviors (Fig. 2K), which are repre­
sentative of the limited selectivity of current appetite­modulating 
drugs. Distinct side effects had led to the market retraction for the 
majority of these anorectic drugs (4, 5). Notably, the recently approved 
lorcaserin, a serotonin receptor 2C agonist, reduced food intake and 
the habituation response in zebrafish (Fig. 2K) and also altered a plei ­
otropy of rodent behaviors (16–19). This lack of behavioral selectivity 
resembles the unspecific neuronal impact observed after rimonabant 
treatment in rodents (20). Anamorelin, a ghrelin receptor agonist, is 
the exception of the here tested compounds being an appetite enhancer 
currently undergoing clinical development. Hence, we demonstrated 
a conserved vertebrate neuropharmacology for many mammalian 
appetite­modulating agents and showed their lack of behavioral se­
lectivity, which is a potential warning sign for neuronal side effects.
Multibehavioral profiles link compounds to their molecular 
mechanism of action independent of the underlying 
chemical structure
Motivated by these findings, we set out to screen for ideal psycho­
active small molecules, that is, compounds that induce only their 
intended single behavioral change. To that end, we performed a 
high­throughput chemical screen to identify these putative selective 
bioactive compounds. We acquired quantitative multibehavioral 
barcodes for a total of 10,421 compounds, each individually tested 
in at least six animals (Fig. 2, L and M). Internal and external con­
trols established screen quality and reproducibility using a standard 
statistical approach (Supplementary Text). This first large­scale multi­
behavioral dataset revealed a remarkable diversity in the impact that 
various compounds have on different behaviors (Fig. 3A) and 
enabled us to address four general questions in drug discovery and 
neuroscience.
First, we tested whether compounds with a similar molecular 
target share similar behavioral phenotypes. A high similarity be­
tween multibehavioral barcodes from a drug with a known mode of 
action and a compound with an unknown target should predict the 
molecular target of the unknown compound. To address this hy­
pothesis, we took advantage of the quantitative nature of the behav­
ioral barcodes to form clusters with similar functional phenotypes. 
Two complementary algorithms [hierarchical clustering (Fig. 3A, left) 
and t­distributed stochastic neighbor embedding (tSNE) (Fig. 3, 
B to D)] segregated behavioral barcodes into compounds that se­
lectively alter a single behavior. Molecules with multibehavioral 
phenotypes populated the transition space between major clusters 
[Fig. 3, A (right) and B, and fig. S3]. Within those, compounds trig­
gered all combinatorial forms of behaviors, such as general loss­ or 
gain­of­function effects. A subset of molecules caused more complex, 
multidimensional phenotypes, such as enhanced acoustic response 
and reduced habituation or reduced food intake and increased 
spontaneous activity [Fig. 3, A (right) and B, and fig. S3]. Barcodes 
of drugs that share one target or multiple targets correlated signifi­
cantly better compared to compounds with unknown mechanisms 
(P = 6 × 10−24; Fig. 3E), thereby confirming the assumption that drugs 
sharing molecular targets trigger similar behavioral consequences. 
Following this logic, we found two compounds with an unknown 
mechanism of action that had a strong correlation with known 
drugs targeting either histamine receptor 1 (H1) or muscarinic ace­
tylcholine receptor 3 (M3), respectively (Fig. 3, F to H). This behav­
ioral phenotype correlation suggested a shared mechanism. In vitro 
competitive binding assays confirmed an interaction of these two 
unknown compounds with the H1 or M3 receptor, respectively (Fig. 3, 
I and J). Thus, we identified two previously unidentified molecules 
binding human H1 and M3 receptor with nanomolar affinity in vitro 
as well as an in vivo behavioral phenotype. The measured binding 
affinities are in the nanomolar range, which is at least one order of 
magnitude stronger compared to compounds normally identified 
by in vitro–targeted high­throughput screens (micromolar to mil­
limolar range; see also Fig. 4C) (21). In sum, a compound’s molecu­
lar target is a predictor for its multibehavioral impact in vivo.
Second, we questioned how a compound’s chemical composi­
tion and structure influences its in vivo bioactivity and behavioral 
selectivity. We did not detect major differences in physiochemical 
properties between inactive and active compounds (Fig. 3K), al­
though it should be mentioned that we intentionally biased our 
screening library toward drug­like molecules. To explore whether 
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similar chemical structures caused related behavioral phenotypes, 
we computed structural similarity scores [two­dimensional (2D) 
Tanimoto similarity] for all molecules within a behavioral cluster 
and compared them to a shuffled control. We found that functional 
clusters were not enriched with similar chemical structures (P = 0.99; 
Fig. 3, L and M). Hence, a compound’s chemical structure is, at least 
in our hands, not a good predictor for its in vivo impact on verte­
brate behavior.
Fig. 2. Available appetite modulators trigger a pleiotropy of behaviors. (A) Schematic of the multibehavior protocol used to test drug impact. Briefly, 2-hour-fasted 
larvae were pre-exposed to a drug for 30 min before multibehavioral profiling. Here, we tested many appetite-modulating drugs used in humans (4, 5). Each drug’s behav-
ioral impact was condensed into a single, quantitative behavioral barcode, which is illustrated here for two classic anorectic drugs—nicotine and rimonabant—in detail 
(n ≥ 12). (B) After providing access to live prey, we quantified larvae’s intestinal food content for 2 hours and condensed the fluorescent traces into two feeding periods 
(F1 and F2). (C to E) Other feeding metrics can be extracted using post hoc, one-way ANOVA, Dunnett’s post test (**P < 0.01 and ***P < 0.001). (F) Simultaneously, larval 
locomotor activity was tracked and summarized in a single metric (S, spontaneous activity). (G) Following these 2 hours, we presented eight consecutive dark flashes to 
larvae and measured their activity. The triggered average response was condensed into two time points: visual periods 1 (V1, first 2 s) and 2 (V2, the following 26 s). 
(H) Next, we presented eight consecutive taps and measured larval kinematic response. Acoustic period 1 (A1) reflects the first 2 s of the triggered average, while A2 re-
flects the following 26 s. (I) Subsequently, a 3-min rest period preceded a sequence of 30 nonsequential taps with short ISI (2 s) used to quantify habituation (H). (J) Last, 
four dark flashes were presented identically as before in (G) to determine lethargy (L1 and L2), which is the activity ratio of the initial and post-dark flash triggered average. 
(K) All 10 behavioral metrics (F1, F2, S, V1, V2, A1, A2, H, L1, and L2) were acquired on a single well basis and normalized to on-plate vehicle controls (n ≥ 24). Each com-
pound was tested in multiple animals (n ≥ 12), and their behavioral effect size and reproducibility were condensed using strictly standardized median difference (SSMD). 
Each square represents an SSMD value (red, higher than control; blue, lower than control) for a single behavioral metric, and jointly, they form a compound’s behavioral 
barcode. The black box indicates the barcodes for nicotine and rimonabant, shown in detail in (B) to (J); the orange box denotes feeding behavior; and the green box 
indicates habituation. *Barcodes shown for drugs tested at 100 M. (L) Overview of all compounds tested in the high-throughput screen using the above protocol. 
Compounds with unknown pharmacology represent chemical structures with unknown biological activity. (M) Overview of all animals used in the high-throughput 
screen. Each compound was tested in multiple animals (n ≥ 6), and effects were quantified relative to on-plate vehicle controls (n ≥ 24). Sixty-two compounds were ex-
cluded in the absence of detectable activity in the last 2 min of the experiment (L1 + L2 = 0), potentially based on the strong anesthetic or lethal impact of the tested 
compound. Behavioral metrics: F, feeding; S, spontaneous activity; V, visual response; A, acoustic response; H, habituation; L, lethargy; 1 or 2, different time periods.
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The zebrafish CNS controls different behaviors by an 
autonomous neuronal circuitry
Third, we hypothesized that if two different behaviors are orches­
trated by the same or overlapping neuronal circuitry, they should 
correlate with respect to their behavioral barcodes. For instance, a 
larva responding to visual stimuli quickly relative to other larvae 
may also respond more quickly to acoustic stimuli if both behaviors 
are controlled by the same neuronal circuitry. If a drug affects this 
shared circuit, we would expect both behaviors to be altered simi­
larly. To quantitatively test this hypothesis, we investigated the cor­
relations among all tested behaviors across all animals. The analysis 
from the behavioral barcodes of more than 10,000 control animals 
revealed strong linear correlation within a specific behavioral group, 
e.g., feeding periods F1 and F2 (Pearson correlation, R > 0.65; two­
tailed, P < 1 × 10−250; fig. S4A); however, different behaviors, e.g., 
visual and acoustic response, did not correlate linearly at a mean­
ingful level (Pearson correlation, R < 0.25; fig. S4A). The interven­
tion with different small molecules did not reshuffle this interbe­
havioral interaction (fig. S4B). In line with this observation, 78% of 
all hits modulated a single behavior based on a standard statistical 
threshold (fig. S4C and Supplementary Text), of which the majority 
up­regulated a behavioral response relative to vehicle control (fig. 
S4D). Overall, the orthogonality of different behaviors in terms of 
drug response suggests that each neuronal circuit has unique fea­
tures targetable by small molecules. Hence, the toolbox from which 
each separate circuit is built does not appear to be the same in the 
zebrafish CNS.
Novel appetite modulators are potent and selective for 
feeding behavior, and the majority are mechanistically 
independent of the main neurotransmitter systems
Last, the existence of ideal, behavior­selective small molecules 
has been questioned, particularly for appetite modulators. Cur­
rent appetite­modulating drugs, which were or are used by humans, 
Fig. 3. Diversity of drug-induced behavioral changes. (A) Hierarchical clustering groups hit compounds with similar behavioral barcodes based on their correlation. 
Dendrogram color code localizes selective clusters shown at higher magnification. (B) tSNE groups hit compounds with similar barcodes using nonlinear probability 
distributions and preserve local distance metrics. All 4801 hits are shown in a 2D space. The tSNE map is false colored, with the primary behavior modulated for a given 
compound. The magnification of the rectangle is shown in (C). (D) tSNE map location of selected hierarchical clusters magnified in (A). (E) Histogram of the pairwise 
Pearson correlation (R) for compound barcodes sharing one or more targets, or compound barcodes with unknown target (two-tailed, two-sample Kolmogorov-Smirnov 
test; line depicts the median). (F) The chemical structure of two novel compounds with unknown target. PubChem compound identifier (CID): unknown 1, 1206526; un-
known 2, 2836278. (G and H) Unknown compound 1 behavioral barcode showed high pairwise Pearson correlation with drugs targeting histamine receptor 1 (H1, R = 
0.70 ± 0.13; mean ± SD), and unknown compound 2 showed high pairwise Pearson correlation with drugs targeting muscarinic acetylcholine receptor 3 (M3, R = 0.72 ± 
0.15). All the relevant barcodes are shown for illustration, and the box shows the mean barcode for all H1 or M3 drugs relevant for correlation. The asterisk (*) depicts 
trans-tripolidine, l-hyoscyamine, and ipratropium bromide. (I and J) Competitive in vitro human receptor binding assays for compound unknown 1 and H1 receptor and 
for compound unknown 2 and M3 receptor with positive control, respectively (n = 4, mean ± SD). (K) Physiochemical properties of all tested compounds. Lines indicate 
the boundaries of Lipinski’s rule of five (26). (L) Cumulative histogram of pairwise structural similarities (2D Tanimoto coefficient, T) for compounds within behavioral 
clusters (fig. S3) or shuffle control (two-tailed, two-sample Kolmogorov-Smirnov test). (M) The tSNE map is falsely labeled with the pairwise structural similarity coefficient 
(T) for the illustrated example compound. Each dot represents a different compound (red, similar structures; blue, dissimilar structures). A Tanimoto coefficient of > 0.85 
reflects very similar structures.
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demonstrated a remarkable lack of behavioral selectivity in zebra­
fish (Fig. 2K). A significant advantage of the multibehavior strategy 
developed here is that it allows for the selection of hits not only based 
on the strength of their effect but also based on their selectivity. Our 
screen identified 373 orexigenic and 145 anorectic molecules based 
on a standard statistical threshold; however, only 194 oroxigenic 
and 74 anorectic molecules were selective for feeding behavior 
(Fig. 4A). The hit rate for selective orexigenic compounds and se­
lective anorectic compounds was 1.8 and 0.7%, respectively. Conse­
quently, the selectivity filter reduced the hit rate by roughly 50%, 
illustrating one advantage. Of these 268 selective appetite modula­
tors, we selected, after inspection of the individual barcodes and the 
chemistry, 11 orexigenic and 11 anorectic candidate compounds with 
unique chemical structures for validation (Fig. 4B and fig. S5). In 
addition, we included five compounds with no significant pheno­
type as a negative control. To date, these candidate small molecules 
have no known biological activity and therefore represent novel in­
tervention options for basic research with potential for clinical de­
velopment. Dose­response studies confirmed their selective impact 
on feeding behavior over a dose range from 0.6 to 20 M (fig. S6, 
A to C). Generally, the drug­induced orexigenic effect was compa­
rable to doubling the fasting period and the magnitude of the ano­
rectic effect to a reduction of fasting times by 50 to 75%. Further 
validation studies in two distinct zebrafish wild­type strains, TL and 
EK, confirmed the compounds’ efficacy and selectivity in two 
distinct genetic backgrounds (fig. S6, D and E). To identify the 
underlying molecular mechanisms, we tested these 22 candidate 
compounds for their binding affinity to 43 human neuronal targets 
using in vitro competitive binding assays (Fig. 4C). We found three 
noteworthy features. First, a few candidate compounds bound with 
nanomolar affinity to targets that are established regulators of feed­
ing behavior in mammals [histamine receptor 1 (22), serotonin re­
ceptor 2B or C (5­HT2B or 5­HT2C) (23, 24), and PBR (25)], thereby 
independently validating our discovery strategy. Second, some com­
pounds interacted with many targets, indicating the presence of 
polypharmacology. Third, most candidate molecules did not bind 
to any of the tested receptors with high affinity, suggesting that they 
act by nontested or unknown molecular mechanisms. Consequently, 
Fig. 4. Identification of novel and selective appetite modulators. (A) Barcodes of all hits modulating feeding behavior selectively based on the SSMD threshold sorted 
by their effect size on feeding period 1 (F1). (B) Twenty-seven structurally novel compounds were selected based on the displayed behavioral barcodes and unique chem-
ical structures (see fig. S5). All compounds were validated, and the complete validation data are shown in Fig. 5 and fig. S6. (C) Heatmap illustration of in vitro target 
binding profiles for all 27 compounds across 43 different human targets. All binding assays were validated with a positive control. Targets: adrenergic receptors (-1A, 
-1B, -1D, -2A, -2B, -1, and -2); dopamine receptors (D1 to D5); -aminobutyric acid (GABA)–A receptor, peripheral benzodiazepine receptor (PBR), and allosteric 
benzodiazepine binding site on rat brain slices (BZP); histamine receptors (H1, H3, and H4); muscarinic receptors (M1 to M5); serotonin receptors (5-hydroxytryptamine, 
5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT3, 5-HT5A, 5-HT6, and 5-HT7); sigma receptors 1 and 2; opioid receptors, -opioid receptor (DOR), -opioid 
receptor (KOR), and -opioid receptors (MOR); and biogenic amine transporters dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin trans-
porter (SERT).
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these 22 orexigenic and anorectic compounds represent unique 
pharmacological tools to selectively modulate feeding behavior in 
zebrafish.
Orexigenic and anorectic candidate compounds enable the 
selective control of appetite in zebrafish and mice
To further challenge the selectivity of these novel compounds, we 
chose four of these for more detailed characterization. These four 
molecules fulfill concepts of drug likeness (Fig. 5A) (26, 27). Orexi­
genic candidate (oC) compounds A and B doubled food intake, 
whereas the two anorectic candidate (aC) compounds C and D re­
duced food intake by more than 50% in zebrafish (Fig. 5, B to E). 
None of the candidate compounds modulated the responsiveness to 
visual (Fig. 5F) or acoustic (Fig. 5G) stimuli, spontaneous activity 
(Fig. 5H), habituation (Fig. 5I), and lethargy (Fig. 5J). aC compound 
D bound to PBR, 5­HT2B, and 5­HT2C receptor with nanomolar 
affinity (Fig. 5, K and L), whereas the other candidate small mole­
cules did not bind to any of the 43 human neuronal targets with a 
millimolar affinity (Fig. 4C). Norfenfluramine, the active metabolite 
of the former anti­obesity drug fenfluramine, binds to 5­HT2B and 
5­HT2C receptors with similar affinities to aC D (28). 5­HT2C re­
ceptor activity is considered the driver for fenfluramine’s anorectic 
effect and is the primary target of the recently approved anti­obesity 
agent lorcaserin (4, 5). To detect potential toxic and mutagenic small­ 
molecule effects, we monitored zebrafish development under the 
exposure of candidate drugs in vivo using light microscopy from 
the single­fertilized cell stage to the 6 dpf behaving larvae. None of 
the candidates had a significant impact on embryological mortality, 
developmental defects, or temporal delays, or on the body length at 
5 dpf, whereas EtOH exposure significantly reduced survival after 
hatching and led to lordosis as reported previously (Fig. 5, M and 
N) (29). As we were unable to detect an impact of the candidate com­
pounds on normal vertebrate development, we tested for a drug 
impact on more subtle behavioral characteristics. These behaviors 
required the analysis of single fish at high temporal and spatial res­
olution and therefore are not suitable for high­throughput screening. 
Fig. 5. “Ideal” candidate compounds’ appetite modulators identified in zebrafish. (A) Chemical structure of four compounds, two orexigenic candidates (oC) and 
two anorectic candidates (aC), with unknown biological activity to date. All structures fulfill Lipinski’s rule of five (26). Two-hour-fasted individual larval zebrafish (7 dpf) 
were pre-exposed for 30 min to candidate compounds before giving access to labeled food. MW, molecular weight. Subsequently, we quantified larval feeding behavior 
(B to E), arousal to visual (F) and acoustic (G) stimuli, spontaneous activity (H), habituation (I), and lethargy (J) (n = 48; one-way ANOVA, Dunnett’s post test, ***P < 0.001). 
ns, not significant. (K and L) Competitive in vitro human receptor binding assays for aC D and 5-HT2B or 5-HT2C receptor with positive control (n = 4, mean ± SD). cpm, 
counts per minute. (M and N) Developmental assay: Embryos were continuously exposed to drugs starting at 1 hpf, and survival rates were recorded until 6 dpf. Body 
length was recorded on day 5. EtOH (350 mM) served as positive control (n = 27; one-way ANOVA, Dunnett’s post test, ***P < 0.001). (O) Example locomotion trace of an 
individual larval zebrafish performing thigmotaxis (wall loving) in daylight and, to a lesser extent, in darkness. The time in the outer circle versus the inner circle was 
quantified as a thigmotaxic index in the presence of candidate compounds (n = 21; one-way ANOVA, Dunnett’s post test, ***P < 0.001). Scale bar, 10 mm. (P) The swim-
ming path of individual larvae in the phototaxis assay during daylight and darkness in which one-half of the well is covered by a visible light–proof shelter. Phototaxis was 
quantified as the time in the open space versus that under the shelter with the treatment of the candidate compounds (n = 21; one-way ANOVA, Dunnett’s post test, ***P < 
0.001). Scale bar, 10 mm. (Q) Turn angles triggered by perpendicular to the larvae’s body axes moving black stripes—the optomotor response—under the influence of 
candidate compounds. If larvae turned in the direction of the stimulus, this was quantified as a correct turn (n = 16; two-tailed, two-sample Kolmogorov-Smirnov test, P > 
0.05). (R) Example swim traces of an individual larval zebrafish in an aversion experimental paradigm, where a noxious stimulus is located at one end of the swimming 
chamber. The time in either half of the tank was quantified as a preference index with treatment of the candidate compounds in daylight or darkness (n = 16; one-way 
ANOVA, Dunnett’s post test, ***P < 0.001). Scale bar, 20 mm. (S) Larval zebrafish swim in bouts, short bursts of motor activity, and these characteristic swim kinetics were 
quantified under the influence of the candidate compounds in a large arena (n = 20; one-way ANOVA, Dunnett’s post test, P > 0.05). Scale bar, 20 mm.
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First, we assessed thigmotaxis (or “wall loving”), which is a validated 
behavioral index for anxiety in animals. Anxiolytic drugs reduce 
thigmotaxis, whereas anxiogenic compounds enhance it in zebra­
fish larvae (30). Candidate compounds A to D did not modulate the 
thigmotaxic response in daylight compared to vehicle control, nor 
did they interfere with the characteristic reduction of thigmotaxis 
observed with the onset of darkness (Fig. 5O). Second, we assessed 
the impact of the candidate compounds on two sensitive visual be­
haviors: phototaxis and the optomotor response. Larval zebrafish 
are attracted by light and averse to darkness, and hence, perform 
positive phototaxis (31). Larvae treated with candidate compounds 
A to D executed phototaxis with similar precision to vehicle­treated 
animals and reduced their place preference during darkness accord­
ingly (Fig.  5P). The optomotor response is an orienting behavior 
evoked by visual motion (32). A closed­loop setup presented a grat­
ing moving perpendicular to the body axes of an individual zebra­
fish. The stimulus elicits a turning behavior within the direction of 
the stimulus. We did not detect a significant impact of candidate 
compound on the correct execution or the turn angle used during 
the optomotor response (Fig. 5Q). Third, we quantified the respon­
siveness of larvae within a novel aversive behavioral paradigm. Larvae 
avoided the presence of noxious stimuli (here, mustard oil) but 
had no preference if presented a non­noxious stimulus (agar). This 
preference was not visually mediated as it was detectable during 
daylight and darkness. Larva treated with the candidate compounds 
avoided the noxious stimuli analogously to vehicle control (Fig. 5R). 
Fourth, larval zebrafish swam spontaneously in an open arena, and 
their locomotion exhibited a characteristic segmentation into an 
individual burst of locomotion, also called a swim bout. We traced 
larval swim locomotion in the presence of the candidate compounds, 
and subsequently performed detailed kinematic analysis. Neither 
larval average swim speed, bout length, bout duration, nor inter­
bout duration was altered by the candidate compounds (Fig. 5S). 
Hence, all the candidate compounds selectively modulated feeding 
behavior in zebrafish larvae, while they showed no detectable impact 
on development and did not interfere with the execution of an array 
of behavioral tasks.
Next, we evaluated the translational potential of candidate com­
pounds, and their generalized applicability to diverse vertebrate 
animals, by testing their efficacy in an adult mouse model. To that 
end, we followed the above logic to evaluate potency and selectivity 
on multiple mice behaviors. Acute systemic small­molecule admin­
istration into the peritoneum [100 mg/kg ip (intraperitoneally); 
n = 3] had no qualitatively detectable impact on alopecia, whisker 
loss, dermatitis, tremor, kyphosis, distended abdomen, tail stiffening, 
nesting, or diarrhea in mature mice. Initially, we focused the quan­
titative behavioral assessment in analogy to the zebrafish behavior 
screen. First, we measured the impact of candidate compounds 
(30 mg/kg ip) on the microstructure of food intake in undisturbed 
mice continuously (Fig. 6A). Mice had access to food ad libitum or 
were fasted for 16 hours before the experiment. These two comple­
mentary paradigms reflect distinct physiological states of appetite. 
oC compounds A and B increased food intake with distinct tempo­
ral dynamics in ad libitum fed mice (Fig. 6, B and C) but had no 
significant impact in 16­hour­fasted mice, probably due to an appe­
tite ceiling effect (Fig. 6D). Anamorelin had a similar impact on food 
intake to the oC compounds. These effects originated from an in­
crease in meal numbers and a reduction of the meal time (fig. S7A). 
oC compound A also increased food­seeking behavior (Fig. 6B). aC 
compounds C and D, on the other hand, reduced food intake in ad 
libitum fed and 16­hour­fasted mice with similar kinetics (Fig. 6, B 
to D) based on a smaller meal size (fig. S7C). Rimonabant induced 
a more potent anorectic effect in the dark phase compared to aC 
compounds; moreover, only rimonabant triggered compensatory 
food intake in the following light phase (fig. S7D). Second, we 
tracked mice locomotion to quantify their spontaneous activity. 
None of the candidate compounds had an impact on undisturbed 
mice locomotion, whereas hypoglycemia induced by insulin injec­
tion reduced locomotion (Fig.  6, E and F). Third, we presented 
short light flashes (5 s), to which mice did not show a detectable 
locomotion response independent of treatment (Fig. 6G). Fourth, 
we applied a single mechanical tap to the mice behavioral chamber, 
causing mice to freeze (Fig. 6H). Only rimonabant treatment mod­
ulated the response to the acoustic tap in mice as observed in zebra­
fish (Fig. 2K). Last, we wanted to further benchmark the behavioral 
selectivity of our compounds by selecting additional behaviors based 
on the previously observed problems with appetite modulators: 
Specifically, we considered glucose homeostasis, psychiatric effects, 
and nausea. First, blood glucose levels were not altered 30 min after 
candidate compound injection in mice, whereas insulin injection 
induced hypoglycemia (Fig. 6E). Blood glucose levels were similar 
across experimental groups before injection (fig. S7E). Second, we 
assessed thigmotaxis in mice, which is a behavioral index for anxi­
ety. None of the candidate compounds modulated the thigmotaxis 
response, whereas rimonabant increased murine anxiety as reported 
previously (Fig. 6I) (20, 33). Third, we evaluated whether candidate 
compounds trigger nausea by measuring conditional taste aversion. 
Candidate compound–treated animals maintained a strong prefer­
ence for conditioned saccharine, whereas LiCl­treated animals re­
duced the intake of this sweet­tasting fluid (Fig. 6J). Fluid intake 
was similar across experimental groups on the test day (Fig. 6J), as 
was saccharine intake on the conditioning day (fig. S7F). Hence, 
candidate compounds did not induce a conditioned taste aversion. 
In sum, all the candidate compounds selectively modulated feeding 
behavior in adult mice, while they showed no detectable impact on a 
series of complex mice behaviors.
Overall, we demonstrated the existence of ideal, behavior­selective 
small molecules in two vertebrate species. In the context of appetite 
modulators, we found 268 previously unidentified compounds, and 
to date, have no described in vivo bioactivity. Twenty­two of these 
candidates were extensively validated, and their behavioral selectiv­
ity was confirmed in multiple follow­up studies. Furthermore, the 
majority of these did not bind to known receptors from main neu­
rotransmitter systems. Four of these, two orexigenic and two ano­
rectic candidate compounds, were benchmarked in a variety of 
sophisticated behavioral assays and were shown to exclusively mod­
ulate appetite in zebrafish and in mice. To further illustrate the gen­
eralizability of this unbiased psychoactive drug discovery strategy, 
we performed a similar analysis for compounds selective for habit­
uation (Supplementary Text and fig. S7). In sum, we identified ideal, 
behavior­selective small molecules that exclusively promote or in­
hibit distinct vertebrate behaviors in two vertebrate species.
DISCUSSION
The large­scale chemical and multibehavior screen developed here 
proved to be a powerful and unbiased tool for (i) the analysis of 
links between a compound’s function, target, and structure; (ii) the 
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identification of novel and ideal neuroactive compounds for differ­
ent vertebrate behaviors; and (iii) the investigation of the interaction 
and interdependency of different vertebrate behaviors. We consider 
these findings to have major implications for drug discovery and 
neuroscience.
First, modern medicine relies on drugs to control disease pro­
gression, and the study of drug action has revealed many biological 
principles. Here, we developed an unbiased in vivo drug screening 
strategy to identify compounds modulating a clinically relevant be­
havior, namely, feeding. These chemical interventions are pertur­
bances to the molecular mechanisms’ underlying behavior and are 
therefore invaluable tools for future in­depth mechanistic under­
standing. Identifying each individual compound’s in vivo mecha­
nism is a heroic future challenge for neuropharmacology. These 
novel molecules, in addition to being selective pharmacological 
tools to the community, are defined chemical backbones for drug 
Fig. 6. Orexigenic and anorectic candidate compounds selectively modulated food intake in mice. (A and B) Ad libitum fed or 16-hour-fasted mice received an in-
traperitoneal injection of candidate compounds (30 mg/kg), and their subsequent food intake was monitored continuously. Their cumulative food intake is shown rela-
tive to vehicle control in (B) (n = 10). ip, intraperitoneally. Summary characteristics of food intake and food-seeking behavior during the dark phase in ad libitum fed (C) or 
16-hour-fasted (D) mice (n = 10; one-way ANOVA, Dunnett’s post test, *P < 0.05, **P < 0.01, and ***P < 0.001). Anamorelin (Ana) and rimonabant (Rim) served as positive 
controls. (E) Blood glucose levels measured 30 min after compound application (n = 10; one-way ANOVA, Dunnett’s post test, ***P < 0.001). Insulin (Ins) served as positive 
control. (F) Spontaneous locomotion of mice quantified 30 min after compound application (n = 10; one-way ANOVA, Dunnett’s post test, *P < 0.05). (G) Triggered average 
displacement response of mice to eight light flashes of 5-s duration and the corresponding light flash index after treatment with candidate compounds (n = 10). 
(H) Triggered average displacement response of mice to eight acoustic taps and the corresponding tap response index after treatment with candidate compounds (n = 
10; one-way ANOVA, Dunnett’s post test, *P < 0.05). (I) Example locomotion trace of individual mice performing thigmotaxis (anxiolytic behavior) treated with vehicle (V) 
or rimonabant (rim). The time in the outer versus the inner square was quantified as a thigmotaxic index after treatment with candidate compounds (n = 10; one-way 
ANOVA, Dunnett’s post test, **P < 0.01). Scale bar, 10 cm. (J) Fluid intake and saccharine preference of mice measured on the test day of a conditioned taste aversion test. 
LiCl served as positive control (n = 8; one-way ANOVA, Dunnett’s post test, ***P < 0.001). 
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development targeting human disease. The conserved neurobiology 
and physiology among zebrafish, mice, and humans will simplify 
these translational ambitions (13, 14). Species differences need to be 
considered, but they exist between all animal model systems. Over­
all, these novel compounds establish the existence of ideal psycho­
active small molecules, namely, compounds triggering only their 
intended, single behavioral change in vivo.
Second, the strength of phenotype screens is their superior abil­
ity to identify “first­in­class” drugs compared to target­based strat­
egies (9). Traditionally, these screens only use effect size in their hit 
selection criteria. Here, we considered compound selectivity at the 
initial stage, which reduced the hit rate by ~50% compared to the 
standard effect size criterion and led to the selection of more specific 
in vivo phenotypes. This selectivity can arise either from the in­
teraction of compounds with unknown molecular targets that are 
unique to a behavior or from systemic drug action balanced opti­
mally across different mechanisms. Both are impossible to identify 
without a whole­organism approach. Taking the above into account, 
future strategies should combine a series of complex behaviors—e.g., 
sexual behavior, feeding, and social interactions—and systematical­
ly quantify the impact of a chemical or genetic intervention with 
unsupervised methods. If throughput is maintained at the scale es­
tablished here, such a pipeline is applicable for combinatorial drug 
discovery, for the chemical rescue of disease­relevant monogenetic 
mutations, and for fragment­based chemical screens. In addition, 
these assays can serve as a standard drug safety control early in pre­
clinical development and may prevent unexpected behavioral side 
effects. Ultimately, this multibehavioral strategy enables selection of 
more specific phenotypes, which may result in a more comprehen­
sive understanding of in vivo drug mechanisms.
Third, diverse schools of thought aim to decode the organiza­
tional principles underlying brain function and its capability to 
control behavior. Here, we find that all tested zebrafish behaviors 
were decoupled from each other across thousands of control ani­
mals and a behavioral selectivity for numerous pharmacological 
interventions. This independence in behavior­generating output 
architecture favors a functional brain structure along orthogonal 
modules in zebrafish, which genetic studies supported even for 
goal­driven behaviors like feeding in distinct animal model systems 
(34–36). For instance, among the best­understood genetically de­
fined brain circuits are the hypothalamic agouti­related peptide­ 
secreting neurons, which have been studied extensively in the past 
20 years and considered crucial for feeding behavior. On the other 
hand, their exclusivity to feeding behavior was recently demonstrated 
to be an oversimplification (37, 38), and these behavioral findings 
are more compatible with the concept of a distributed neuronal 
processing brain architecture, which may better mirror the com­
plexity observed in the dense anatomical reconstruction of brain 
volumes, the diversity of secreted neuropeptides, and the dynamics 
of individual neurons’ gene expression (39, 40). Future work can 
contribute to the resolution of this ongoing discussion by exploiting 
the interaction of selective molecules with the in vivo complexity of 
an intact brain generating selective behavioral output.
In conclusion, our unbiased and large­scale behavioral findings 
jointly establish the advantages of multibehavioral screening for 
psychoactive compounds, propose a largely independent and mod­
ular organization of neural circuits that generate behavior in the 
larval zebrafish, and demonstrate the feasibility to control verte­
brate behavior with novel, behavior­selective compounds.
MATERIALS AND METHODS
Zebrafish
Adult zebrafish (Danio rerio) from the mitfa−/− (nacre), TL, and EK 
strain were maintained on a 14­hour light/10­hour dark cycle at 
28°C and fed three times daily with live Artemia and/or powder 
food (O.range, INVE Aquaculture, The Netherlands). All protocols 
and procedures involving zebrafish were approved by the Harvard 
University/Faculty of Arts and Sciences Standing Committee on 
the Use of Animals in Research and Teaching (Institutional Animal 
Care and Use Committee). If not stated differently, larvae from the 
mitfa−/− (nacre) strain were used in the experiments.
Zebrafish larvae production and standardized  
growth conditions
Larvae from bucket crosses were collected and pooled in blue water 
[density of > 5 ml per larva (pH 7.2); sodium bicarbonate buffer, 
methylene blue (1 g/liter), and instant ocean salt (0.2 g/liter)]. Live 
embryos were selected ~24 hours post­fertilization (hpf) and trans­
ferred to the automated growth system in 2­liter tanks (fig. S1). The 
automated growth system exchanged 50% of the larvae’s growth 
water [> 5 ml per larva (pH 7.2); sodium bicarbonate buffer and 
instant ocean salt (0.2 g/liter), continuously oxygenated] four times 
daily and fed the larvae starting at 4 dpf with a bolus of > 30 ml of 
fresh paramecium culture [optical density at 490 nm (OD490) ≥ 0.2] 
10 min after each water exchange. The automated system was main­
tained at 28°C and at a 14­hour light/10­hour dark cycle.
Paramecium production and labeling
Protozoan pellets (Carolina Biological Supply, Burlington, USA) were 
dissolved in boiling larval growth water. After cooling, live parame­
cia and RotiGrow Plus (Reed Mariculture, Campbell, USA) were 
added to the protozoan water, and the culture was incubated for a 
minimum of 2 days at 28°C before use. All paramecium strains were 
cultured using this protocol and were originally obtained from 
Ward’s Science (Rochester, USA). Visual inspection of paramecium 
size and structure enabled us to distinguish among Paramecium 
caudatum, Paramecium bursaria, or Bdelloidea. If not stated different­
ly, P. caudatum was used for all experiments. All paramecium cultures 
were visually inspected for purity before use with light microscopy. 
Paramecia were fluorescently labeled using previously described 
protocols (15).
Zebrafish imaging platform
The basic concept comes from the infrared (IR) macroscope de­
scribed by Jordi et al. (15). All components were identical, except 
for the following changes, which were made to reduce cost and sim­
plify construction, to improve the signal­to­noise ratio, and to en­
able diverse behaviors: (i) White light (LZ4, LED Engine, San Jose, 
USA) was filtered using an ultraviolet­IR (UV­IR) band­pass filter 
(HOYA, Tokyo, Japan). (ii) Fluorescent excitation light was gener­
ated using a single, cooled 740­nm light­emitting diode (LZ4, LED 
Engine), a lens (12° uniform spot, LED Engine), and a squared light 
diffuser (Thorlabs, Newton, USA). (iii) The new generation of 
IDS camera was used with significantly improved sensitivity in our 
hands in the 780­ to 820­nm range (emission range of fluorophore) 
(IDS UI­3370CP­NIR, IDS, Obersulm, Germany). (iv) A push­tap 
solenoid (Guardian Electric 28P­I­12D, Allied Electronics, Texas, 
USA) enabled us to deliver acoustic stimuli. Four instruments were 
constructed to enable higher throughput. Emission light calibration 
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was conducted using DiR dye (Molecular Probes, Eugene, USA) 
dissolved in dimethyl sulfoxide (DMSO) at different concentrations 
and recording fluorescent emission from the same probes for 100 ms 
on all the different behavioral imaging platforms. All image plat­
forms showed very similar sensitivity for fluorescence detection.
Zebrafish homeostatic state experiment
Larvae (7 dpf) were collected from the automated system, washed 
to remove remaining paramecia, and transferred into petri dishes. 
Dead and malformed larvae were discarded upon visual identifica­
tion. Larvae were randomly split into a fed group, a 2­hour­fasted 
group, and a 4­hour­fasted group. All groups were timed to enable 
simultaneous behavioral measurements. For the feeding assay, larval 
zebrafish were transferred to a single well of a flat­bottom 96­well 
plate (Falcon, VWR, USA) in 150 l of larval growth water. Within 
1 min before starting behavioral imaging, 50 l of labeled paramecium 
culture [OD490nm > 0.5, > 500 paramecia per well; see Jordi et al. (15) 
for calibration] was added, the plate was transferred to the behav­
ioral imaging platform, and the experiment was started. For all other 
behaviors, larval zebrafish were transferred to a single well of a 
flat­bottom 96­well plate in 200­l larval growth water, subsequently 
transferred to the behavioral imaging platform, and each experiment 
was started.
Zebrafish high-throughput chemical screen
Larvae (7 dpf) were collected from the automated system 30 min 
after the last automatic paramecium supply, washed to remove re­
maining paramecia, and transferred into petri dishes. Dead and 
malformed larvae were discarded upon visual identification. Petri 
dishes were cooled at 4°C for 5 to 10 min to immobilize larvae. Two 
immobilized, randomly selected larval zebrafish were transferred to 
a single randomly selected well of a flat­bottom 96­well plate in 
120 l of larval growth water. Larvae were fasted for 2 hours at room 
temperature (23° to 24°C) within the multiwell plate. Subsequently, 
larvae were pre­exposed to 30 l of compounds (final concentration 
of 10 M in 0.15% DMSO, if not stated differently) for 30 min. 
Within 1 min before starting behavioral imaging, 50 l of labeled 
paramecium culture (OD490nm > 0.5, > 500 paramecia per well) was 
added, the plate was transferred to the behavioral imaging platform, 
and the experiment was started. The following compound libraries 
were tested: DIVERSetE library (ChemBridge, San Diego, USA, 
≥95% purity), Spectrum library (Microsource Discovery Systems, 
Gaylordsville, USA, ≥95% purity), Prestwick library (Prestwick 
Chemical, Illkirch, France, ≥95% purity), and Biomol Neurotrans­
mitter library (BML­2810, Enzo Life Sciences, Farmingdale, USA, 
≥95% purity). Individual compounds were reordered from suppli­
ers. For the screen, each compound was tested in six animals. A 
subset of 530 compounds was tested in 12 or 18 animals because 
identical compounds were contained in multiple libraries. Lorcase­
rin (AdooQ Bioscience LLC, CA, USA), rimonabant­HCl (Sigma­ 
Aldrich, MO, USA), and anamorelin (AdooQ) were acquired at 
>98% purity.
Validation experiments of zebrafish high-throughput screen 
and other multibehavioral experiments
Validation (Fig. 5 and figs. S6 and S7), preliminary dose response 
(fig. S2A), and appetite­modulating drug (Fig. 2) experiments were 
conducted similarly to above. Compounds and different doses 
were randomly distributed across validation plates, and experiments 
were repeated on at least three different days to acquire representative 
compound effects. One larva was tested individually for each com­
pound and dose. Larvae were not cooled to simplify platting.
Zebrafish multibehavioral experiment
The experimental flow is graphically depicted in Fig. 2A. We col­
lected a fluorescent image, required to measure intestinal parame­
cium content, with 100­ms exposure time every min for 2 hours and 
simultaneously used transmitted IR images to track in real time the 
spontaneous swimming activity of all zebrafish larvae at a camera 
frame rate of 10 Hz. After this initial 2­hour feeding experiment, 
eight dark flashes (750 ms, 30­s ISI) followed by eight taps (30­s ISI) 
were presented to larvae. This period was followed by a 3­min rest 
period, followed by the presentation of 30 taps with 2­s ISI (habitu­
ation). After habituation, four dark flashes (750 ms, 30­s ISI) were 
presented to the larvae before completion of the experiment.
Zebrafish screen data acquisition and behavioral barcoding
The principles for data acquisition represent the code presented by 
Jordi et al. (15) but were further optimized. The following adapta­
tions were made, enabling the measurement of two larvae per well: 
Larval intestines were identified using intensity and size thresholds. 
This thresholding led to a number of particles per well, which were 
sorted by signal strength (area × mean intensity), and the top two 
were stored as intestinal traces. Kinematic traces were quantified as 
described by Kokel et al. (41), where the number of times an animal 
crosses any of three parallel imaginary lines is counted. We counted 
larval line crosses for each well at a frame rate of 10 Hz. Next, the 
data were preprocessed as follows on a well­by­well basis (Fig. 2): 
The fluorescence measurements were binned down to two time pe­
riods reflecting the accumulated fluorescence in the first 40 min 
(F1, feeding period 1) and the last 80 min of the experiment (F2, 
feeding period 2), respectively. Concurrent larval locomotion activ­
ity was condensed into one bin for the entire 2 hours (S, sponta­
neous locomotion). Next, we aligned the repeats of the initial eight 
dark flashes, the eight taps, and the four post­dark flashes to con­
struct triggered averages, each 28 s in length, using an interpolation­ 
based alignment method to generate a standard time base. These 
time traces were normalized to the period preceding a given stimu­
lus (2 s) to account for differences in spontaneous locomotion. 
These traces were then condensed into two metrics for the visual 
response (V, visual) and the acoustic response (A, acoustic), the 
first comprising the initial 2 s of the response (period 1) and the 
second comprising the remaining 26 s (period 2). The ratio between 
the values for the initial and final dark flashes quantified animal’s 
lethargy (L1 and L2, lethargy periods 1 and 2). The 30­tap habitua­
tion stimulus was condensed into a single number by taking the 
ratio of the maximum response values of the last 15 taps to the first 
15 taps (H, habituation). Next, the entire plate was normalized to 
the median of on­plate vehicle controls to yield a fold change with 
respect to the vehicle. After this final calculation on a per­plate ba­
sis, we calculated the SSMD for the values from each compound by 
matching its replicate wells across plates and their corresponding 
vehicle control wells. The statistical advantages and limitations of 
SSMD are extensively discussed elsewhere (42). This calculation was 
performed on the individual metrics coming from the feeding be­
havior (F1 and F2), spontaneous activity (S), visual response (V1 
and V2), acoustic response (A1 and A2), habituation (H), and 
lethargy (L1 and L2). These 10 SSMD values per compound were 
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termed a given compound’s barcode and were used for the cluster­
ing detailed below (43). For the calculation of confidence boundaries, 
we performed the same SSMD calculations for all vehicle­treated 
animals split into measurements of six animals analogously to the 
per­compound measurement outlined before. This entire process was 
performed in a blinded fashion; i.e., there was no a priori knowledge 
of compounds before hit determination. For the analysis of the can­
didates’ validation (Fig. 5 and figs. S6 and S7), preliminary dose 
response (fig. S2A), and anti­obesity drug (Fig. 2) experiments, we 
slightly modified the aforementioned process to enable measure­
ment of a single larva per well: Fluorescent traces were not binned, 
and the activity traces were condensed to 1­min bins using the 
fluorescent reads as a common time base. For dark flash, tap, and 
post­dark flash, we performed trigger­average alignment as above. 
Habituation reflects the activity ratio of the mean of the last three 
taps and the initial three taps, if not indicated differently. Valida­
tion barcodes were constructed accordingly.
Compound structural similarity, physiochemical properties, 
and target annotation
Compounds from the Biomol Neurotransmitter, Spectrum, and Prestwick 
libraries were matched to their PubChem CID on the basis of the 
Chemical Abstracts Service (CAS) number, which was provided by 
the supplier. The ChemBridge library was annotated to CIDs by 
the vendor. PubChem was used to calculate pairwise structural sim­
ilarity (2D Tanimoto coefficient) between all compounds and to trans­
form CIDs into chemical structure line notations, i.e., simplified 
molecular input line entry system (SMILE) (44). Compound phys­
iochemical properties were computed on the basis of compounds 
SMILE using Open Babel implemented in ChemMine (45). Targets 
were annotated to CIDs curated from publications and patents using 
the BindingDB (46). If no target was found, the ChEMBLdb 
was searched, followed by PDSPKi, and finally PubChem (47, 48). 
Of the 3334 known molecules, 2007 were assigned a single target. 
Cautionary notes: (i) Many molecules may have a known or un­
known polypharmacological mechanism of action. For simplicity, 
here, the first identified target was used for annotation. (ii) Com­
pound target annotation in many cases is based on in vitro or cellular 
screens; hence, a direct translation to in vivo may reflect an over­
simplification. These and other obvious limitations must be con­
sidered when assessing the relevance of target annotation.
Clustering and correlation
Hierarchical clustering (distance metric—correlation; linkage— 
average), tSNE (perplexity = 25), and Pearson correlation analysis 
were performed in MATLAB (R2015a, The Mathworks, Massachusetts, 
USA) (49).
Receptor binding assay
In vitro binding assays were performed by the U.S. National 
Institute of Mental Health Psychoactive Drug Screening Pro­
gram (48). Detailed descriptions of the method and data analysis 
can be found at https://pdspdb.unc.edu/pdspWeb/content/
PDSP%20Protocols%20II%202013­03­28.pdf.
Zebrafish developmental assay
Fertilized embryos were collected following natural spawning and 
visually inspected, and three healthy randomly selected embryos were 
placed into a well of a standard flat­bottom six­well plate (VWR) 
filled with larvae’s growth water. Each well was treated with either 
DMSO, candidate compounds A to D (10 M), or EtOH (350 mM) 
at 1 hpf. Six­well plates were maintained on a 14­hour light/10­hour 
dark cycle at 28°C. Every 12 hours, each embryo was inspected 
with a stereomicroscope and scored for survival until 6 dpf. At 5 dpf, 
images were acquired with a stereomicroscope, and body length was 
measured using ImageJ.
Zebrafish thigmotaxis assay
Larvae (7 dpf) were collected from the automated system, washed to 
remove remaining paramecia, and transferred into petri dishes. 
Larvae were fasted for 2 hours in a standard flat­bottom six­well 
plate before exposure to candidate compounds (10 M) for 30 min. 
Subsequently, larval swimming behavior was tracked at 10 Hz by a 
camera (IDS UI­3370CP­NIR) positioned above the plate, which was 
illuminated with an IR light source from below. The camera had an 
IR filter mounted to avoid interference from visible light. Briefly, 
the tracking algorithm subtracted a 10­frame running­average back­
ground image, applied a size threshold to identify the fish, and ex­
tracted its coordinates, heading angle, etc. After recording 10 min of 
swimming behavior in daylight, the ambient light was shut off, and 
10 min of swimming was recorded in darkness. For data analysis, 
each well was split into two equal­sized areas: border and center. 
The time periods each fish spent in an area based on its coordinates 
were summed, and the thigmotaxis index was calculated as follows: 
[Time(wall) − Time(center)]/Time(total).
Zebrafish phototaxis assay
The phototaxis experiment was executed identically to the thigmo­
taxis assay. The main difference was that one­half of the well was 
covered with an IR light–proof shelter (no visible light passes; 
McMaster, New Jersey, USA). For data analysis, each well was split 
into two equal­sized areas: shelter and open space. The time periods 
each fish spent in an area based on its coordinates were summed, 
and the phototaxis index was calculated as follows: [Time(open 
space) − Time(shelter)]/Time(total).
Zebrafish optomotor response
Larvae (7 dpf) were collected from the automated system, washed to 
remove remaining paramecia, and transferred into a petri dish. Larvae 
were fasted for 2 hours in the petri dish before exposure to candi­
date compounds (10 M) for 30 min. Subsequently, their optomotor 
response was quantified using a closed­loop imaging system and 
code, as previously described (32).
Zebrafish aversion assay
Zebrafish larvae (7 dpf from the automated system) were fasted for 
2 hours in a petri dish before exposure to candidate compounds 
(10 M) for 30 min. Next, the larvae, including the drug, were trans­
ferred into a custom­built rectangular well with the following di­
mensions: 1.8 cm by 9.2 cm by 0.4 cm (w × l × h). A chamber at the 
width side allowed for the placement of a firm agar pad. One agar 
pad (2% agar in larvae’s growth water) contained mustard oil [nox­
ious stimuli, 20% (v/v) allyl isothiocyanate; Sigma­Aldrich] and the 
other did not contain additives. After recording 10 min of swimming 
behavior in daylight, the ambient light was shut off and 10 min of 
swimming was recorded in darkness using the same setup and algo­
rithm as for thigmotaxis and phototaxis. Aversion was quantified 
by splitting the rectangle into two equal­sized halves: noxious and 
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agar side. The time periods each fish spent in an area based on its 
coordinates were summed, and the aversion index was calculated as 
follows: [Time(noxious) − Time(agar)]/Time(total).
Zebrafish free-swimming
Larvae (7 dpf) were collected from the automated system, washed 
to remove remaining paramecia, and transferred into a petri dish. 
Larvae were fasted for 2 hours in the petri dish before exposure to 
the candidate compounds (10 M) for 30 min. Subsequently, larval 
free­swimming behavior was recorded for 10 min in daylight within 
a standard flat­bottom petri dish (diameter, 100 mm) using the al­
gorithm outlined above for thigmotaxis and phototaxis. Extracted 
coordinates with associated time stamps were used to calculate av­
erage swim speed, bout length, and bout frequency.
Mice
Four­month­old male C57BL/6J mice (Charles River, Sulzfeld, 
Germany) were individually housed in wire­mesh hanging cages or 
in standard mice cages at room temperature (21° ± 1°C) and at an 
artificial 12­hour light/12­hour dark cycle. Animals were able to 
see, hear, and smell their conspecifics in neighboring cages and were 
not socially isolated. Water, food (mice chow­3436, Kliba Nafag, 
Kaiseraugst, Switzerland), and bedding were provided ad libitum, if 
not indicated differently. All procedures for mice handling and ex­
perimental interventions were according to Swiss Animal Welfare 
laws, approved by the “Kantonales Veterinäramt Zürich,” and con­
form to the principles of UK regulations. Animals were adapted to 
novel housing situations and feeding schedules at least for 1 week. 
All experiments were conducted three times with saline injections 
before drug administration to habituate the animals to the experi­
mental procedure.
Mice compound application
Individual compounds (candidate compounds, rimonabant, and 
anamorelin) were obtained from suppliers at a purity of > 95% and 
dissolved in DMSO (Sigma­Aldrich). Compounds were injected 
intraperitoneally and diluted in 0.9% NaCl [maximum, 8% DMSO; 
maximum, 250 l per 10 g of body weight (BW)] at a concentration of 
30 mg/kg, if not stated differently. LiCl (0.15 M, Sigma­Aldrich) 
and insulin (1 U/kg; Humalog, Lilly, IN, USA) were dissolved in 
0.9% NaCl directly (no DMSO; maximum, 250 l per 10 g of BW).
Mice feeding behavior
Ad libitum fed or 16­hour­fasted mice received an intraperitoneal 
injection of candidate compounds within 15 min before dark onset. 
Food was made available at dark onset to the 16­hour­fasted mice. 
Food intake was measured continuously in undisturbed mice using 
an automated system (BioDAQ, Research Diets, NJ, USA). This sys­
tem measures food hopper weight (±0.01 g) at 1­Hz resolution. The 
microstructure of feeding was analyzed using proprietary software 
(BioDAQ Monitoring Software) as follows: Absolute food hopper 
weight changes smaller than 0.02 g within a 5­s time interval 
were counted as food­seeking bouts. Absolute food hopper weight 
changes of 0.02 g or larger represent a meal and were summed into 
a single meal based on a 10­min intermeal interval.
Mice blood glucose
Three­hour­fasted mice received a tail cut for immediate blood 
glucose measurement (Breeze 2, Bayer AG, Leverkusen, Germany). 
Subsequently, candidate compounds were injected intraperitoneally, 
and mice were returned to their home cage for 30 min before a second 
blood glucose measurement was performed as described before.
Mice kinematic measurement
Three­hour­fasted mice were injected intraperitoneally with a can­
didate compound and were placed into a clear plastic chamber 
(58 cm by 38 cm by 20 cm) 30 min after injection. Subsequently, mice 
displacement was tracked online at 16 Hz by a camera (Logitech 
C930e HD) positioned above the chamber that was illuminated 
with an IR light source from below. The camera had an IR filter 
mounted to avoid interference from visible light. Briefly, the track­
ing algorithm subtracted a 10­frame running­average background 
image, applied a size threshold to identify the mouse (minimum 
motion detected was 5 mm), and extracted its coordinates. Extracted 
coordinates with linked time stamps were used to calculate dis­
placement. Mice behavior was recorded for 15 min in complete 
darkness, and the final 10 min were analyzed.
Mice tap and white light response
Three­hour­fasted mice were injected intraperitoneally with a can­
didate compound and were tracked in complete darkness 30 min 
after injection as outlined above. After recording undisturbed be­
havior for 15 min, eight taps (75 to 85 dB) were applied to the mouse 
cage with an ISI of 30 s. We aligned the repeats of the eight taps to a 
triggered average using an interpolation­based alignment method 
to generate a standard time base. These time traces were normalized 
to the period preceding a given stimulus (2 s) to account for differ­
ences in spontaneous locomotion, and the tap response index was 
calculated as follows: median displacement (time period of 2 to 28 s 
after the tap)/median displacement (time period of 0 to 2 s immedi­
ately after the tap). The response of mice to white light flashes was 
tested similarly to the tap response. Instead of taps, eight periods of 
5­s white light flashes (300 lux, UV, and IR light filtered) were re­
peated every 30 s. The flash response index was calculated as follows: 
median displacement (time period of light)/median displacement 
(time period of darkness).
Mice thigmotaxis assay
Three­hour­fasted mice were injected intraperitoneally with a can­
didate compound and were tracked in complete darkness for 30 min 
after injection with the apparatus outlined above. For data analysis, 
the cage was split into two equal­sized areas: border and center 
square. The time periods that each mouse spent in an area based on 
its coordinates were summed, and the thigmotaxis index was calcu­
lated as follows: [Time(wall) − Time(center)]/Time(total).
Mice conditioned taste aversion test
Fourteen­hour water­deprived mice received access to 0.15% sac­
charin (Sigma­Aldrich) solution for 2 hours on the conditioning day. 
Next, candidate compounds were injected intraperitoneally, saccha­
rine was removed, and water access was provided for 8 hours. On 
the subsequent test day, 14­hour water­deprived animals received 
sim ultaneous access to water and saccharine, and their fluid intake 
was measured for 6 hours.
Statistics
All experiments were randomized, and data analysis was performed 
blindly. Statistical tests were used as appropriate and performed using 
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GraphPad Prism 7.02 (GraphPad Software, California, USA) or 
MATLAB. Data are presented as mean ± SEM, if not indicated 
differently.
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